Parkinson’s Disease Medication Use

    Basic Details
    Date Posted
    Friday, June 7, 2013
    Status
    Complete
    Medical Product
    carbidopa
    combination product of carbidopa
    entacapone
    levodopa
    levodopa and entacapone (Stalevo)
    Description

    Modular program-based one-time assessment of the use of three different drugs for Parkinson’s Disease, carbidopa/levodopa, entacapone, and combination product carbidopa, levodopa, and entacapone (Stalevo), in the Mini-Sentinel Distributed Database. Two categories of counts were generated: (1) incident counts with respect to each of the medications, and (2) prevalent counts (i.e., counts of users with at least one dispensing during the period of interest [January 2000- December 2010]). Modular programs are adaptable standardized programs. Results were generated using Modular Program 1; click here for more information. Programs were executed in February 2011.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2000 - December 31, 2010
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)